Antibody performance is often discussed in terms of affinity, specificity, application data, and lot-to-lot consistency. Of course, these are all important. But for teams developing diagnostic or translational assays, performance data are only part of the evaluation.
An additional, and significant, part is process.
As an antibody moves from research use toward diagnostic application, the questions around it change. It is no longer enough to ask only whether the antibody binds the intended target. Developers also need to understand how the antibody was made, how it was characterized, how its performance is documented, how changes are controlled, and whether the supplier can support the level of traceability expected in a regulated or audit-facing environment.
This is where quality management systems and ISO certifications become relevant.
A quality management system does not make a poor antibody better. It doesn’t replace scientific validation. But it does create a documented framework for controlling how products are developed, manufactured, tested, reviewed, released, and supported over time. For diagnostic developers, that framework can make the difference between a useful research reagent and a practical development partner.
What ISO 9001 and ISO 13485 actually mean
ISO certifications are often referenced broadly (including on our own website), but the distinctions matter.
ISO 9001 is a general quality management standard. It applies across many industries and focuses on whether an organization has defined processes for consistently meeting customer and regulatory requirements, managing quality, and improving over time.
ISO 13485 is more specific to medical devices and related services. It places greater emphasis on documentation, traceability, risk management, process control, and regulatory expectations across the product life cycle.
Therefore, ISO 13485 is more relevant when the work is connected to diagnostic development because it is aligned with the kind of controls and records that medical diagnostics teams often need to evaluate.
While the certification signals that certain systems exist and are being maintained, the practical question is how those systems show up in the product, the documentation, and the supplier’s ability to support the customer’s development path.
Quality management systems make process visible
Antibodies are easy to reduce to a catalog number, clone name, or vial label. In practice, each antibody represents a series of decisions and process steps.
At Aviva, those steps include antigen design, immunization, screening, clone selection, recombinant expression, purification, characterization, formulation, application testing, and documentation. For assay development, the process extends further into epitope binning, antibody pair selection, matrix testing, assay optimization, stability assessment, and manufacturing transfer.
With respect to process, a quality management system helps define how these steps are performed and recorded. It provides procedures for how materials are handled, how data are reviewed, how deviations are managed, how changes are controlled, and how product records are maintained.
It also controls activities that may seem less visible to the customer but still shape product reliability. Training is one example. In a mature quality management system, training is not informal or assumed: it is documented, role-specific, reviewed, and connected to the procedures people are expected to follow. That matters because product consistency depends not only on written protocols, but on whether trained personnel are following those protocols correctly and consistently.
Customer feedback is another important controlled process. Positive feedback, technical concerns, complaints, and product performance issues should not disappear into email threads or informal conversations. They need to be captured, reviewed, investigated where appropriate, and used to improve products, documentation, support, and internal processes.
A reagent that performs well is useful, but in some cases, a reagent that performs well and comes with a controlled, documented, reproducible process is essential.
For diagnostic development, “binds the target” is not enough, we need to ask: does this antibody behave predictably enough, in the right format and matrix, to support the next stage of development?
When evaluating a supplier for diagnostic applications, it's useful to assess both scientific capability and quality management infrastructure:
What quality certifications does the organization hold?
ISO 9001 and ISO 13485 are not interchangeable. Both can be valuable, but ISO 13485 is generally more relevant for diagnostic-oriented work.
How are personnel trained on controlled procedures?
Training should be documented and connected to the procedures, equipment, and quality responsibilities relevant to each role. This is especially important for processes that affect product development, manufacturing, testing, release, and customer support.
How was the antibody characterized?
Look beyond a single application image. Depending on the project, affinity, specificity, cross-reactivity, epitope behavior, and matrix performance may all matter.
What documentation can be provided?
Ask about certificates of analysis, lot records, release criteria, characterization data, stability information, and change control processes.
How is lot-to-lot consistency managed?
Long-running programs need reagents that can be produced and supported consistently. Recombinant antibodies can be helpful because the sequence is defined and production can be more tightly controlled.
Can the supplier support assay-specific development?
For sandwich ELISA and other biomarker assays, the best antibody is not always the best assay component. Pair compatibility, epitope accessibility, signal-to-background, dynamic range, and matrix effects all shape assay performance.
Can the supplier support audits or quality review?
Diagnostic developers may need partners who can respond to quality questionnaires, provide structured documentation, and explain how products are developed and controlled.
How is customer feedback handled?
Ask whether positive feedback, technical issues, complaints, and product concerns are formally captured and reviewed. A supplier’s ability to learn from customer experience is part of how a quality management system supports continuous improvement.
Download our progranulin case study to see how Aviva developed a high-affinity antibody pair for progranulin detection, from recombinant antibody discovery and characterization through pair selection and ELISA validation.